...
ird-img

Opus Genetics, Inc., Common Stock

IRD

NAQ

$0.9871

+$0.16

(19.28%)

1D

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$0
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
724.55K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.81 L
$3.4 H
$0.9871

About Opus Genetics, Inc., Common Stock

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan. more

Returns

Data is not properly formatted.

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue-589.00K39.85M19.05M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":1.48,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":47.8,"profit":true}]
Cost of Revenue----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses9.47M23.29M21.62M29.61M[{"date":"2020-12-31","value":31.97,"profit":true},{"date":"2021-12-31","value":78.66,"profit":true},{"date":"2022-12-31","value":73.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(9.47M)(22.70M)18.23M(10.56M)[{"date":"2020-12-31","value":-51.94,"profit":false},{"date":"2021-12-31","value":-124.57,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-57.96,"profit":false}]
Total Non-Operating Income/Expense(15.15M)(33.99M)(23.00K)589.00K[{"date":"2020-12-31","value":-2572.84,"profit":false},{"date":"2021-12-31","value":-5770.46,"profit":false},{"date":"2022-12-31","value":-3.9,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(24.62M)(56.69M)18.20M(9.97M)[{"date":"2020-12-31","value":-135.25,"profit":false},{"date":"2021-12-31","value":-311.45,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-54.79,"profit":false}]
Income Taxes----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(24.62M)(56.69M)17.89M(9.99M)[{"date":"2020-12-31","value":-137.63,"profit":false},{"date":"2021-12-31","value":-316.93,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-55.83,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(24.62M)(56.69M)17.89M(9.99M)[{"date":"2020-12-31","value":-137.63,"profit":false},{"date":"2021-12-31","value":-316.93,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-55.83,"profit":false}]
EPS (Diluted)-(9.11)0.76(0.47)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1202.05,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-62.51,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IRD
Current Ratio 10.68

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IRD
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IRD
Debt Ratio Lower is generally better. Negative is bad. 0.09
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.91

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IRD
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.00
EV/R 0.00
EV/Ebitda NM

FAQs

What is Opus Genetics, Inc. share price today?

Opus Genetics, Inc. (IRD) share price today is $0.9871

Can Indians buy Opus Genetics, Inc. shares?

Yes, Indians can buy shares of Opus Genetics, Inc. (IRD) on Vested. To buy Opus Genetics, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IRD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Opus Genetics, Inc. be purchased?

Yes, you can purchase fractional shares of Opus Genetics, Inc. (IRD) via the Vested app. You can start investing in Opus Genetics, Inc. (IRD) with a minimum investment of $1.

How to invest in Opus Genetics, Inc. shares from India?

You can invest in shares of Opus Genetics, Inc. (IRD) via Vested in three simple steps:

  • Click on Sign Up or Invest in IRD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Opus Genetics, Inc. shares
What is Opus Genetics, Inc. 52-week high and low stock price?

The 52-week high price of Opus Genetics, Inc. (IRD) is $3.4. The 52-week low price of Opus Genetics, Inc. (IRD) is $0.81.

What is Opus Genetics, Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Opus Genetics, Inc. (IRD) is

What is Opus Genetics, Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Opus Genetics, Inc. (IRD) is 0.00

What is Opus Genetics, Inc. dividend yield?

The dividend yield of Opus Genetics, Inc. (IRD) is 0.00%

What is the Market Cap of Opus Genetics, Inc.?

The market capitalization of Opus Genetics, Inc. (IRD) is

What is Opus Genetics, Inc.’s stock symbol?

The stock symbol (or ticker) of Opus Genetics, Inc. is IRD

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top